CD8A and neoplasm: We demonstrated that qPB could be used to produce patient-derived CARiC9-20/19 CAR-T cells with many desirable attributes, including a high proportion of CAR+ TSCM, balanced CD8/CD4 ratio, low exhaustion and senescence marker expression, high expansion capacity, and high anti-tumor efficacy.